← All trials
NCT05126238
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2021
- Primary completion
- Dec 30, 2023
- Completion date
- Nov 30, 2024
- First posted
- Nov 18, 2021
- Last posted
- Nov 18, 2021
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Negovsky Reanimatology Research InstituteLead sponsor
- Negovsky Reanimatology Research InstituteReponsible party - principal investigator
- Negovsky Reanimatology Research InstituteOverall official - principal investigator
- Demikhov Municipal Clinical Hospital 68Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.